These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 15647409

  • 21. Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections.
    Sörgel F, Kinzig M.
    Eur J Surg Suppl; 1994; (573):39-44. PubMed ID: 7524794
    [Abstract] [Full Text] [Related]

  • 22. Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure.
    Valtonen M, Tiula E, Takkunen O, Backman JT, Neuvonen PJ.
    J Antimicrob Chemother; 2001 Dec; 48(6):881-5. PubMed ID: 11733473
    [Abstract] [Full Text] [Related]

  • 23. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
    Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP.
    J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
    [Abstract] [Full Text] [Related]

  • 24. Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002.
    Frei CR, Burgess DS.
    Clin Ther; 2008 Dec; 30(12):2335-41. PubMed ID: 19167592
    [Abstract] [Full Text] [Related]

  • 25. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects.
    Chandorkar G, Huntington JA, Gotfried MH, Rodvold KA, Umeh O.
    J Antimicrob Chemother; 2012 Oct; 67(10):2463-9. PubMed ID: 22773741
    [Abstract] [Full Text] [Related]

  • 26. Molecular Adsorbent Recirculating System (MARS(®)) removal of piperacillin/tazobactam in a patient with acetaminophen-induced acute liver failure.
    Ruggero MA, Argento AC, Heavner MS, Topal JE.
    Transpl Infect Dis; 2013 Apr; 15(2):214-8. PubMed ID: 23279615
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.
    Bauer SR, Salem C, Connor MJ, Groszek J, Taylor ME, Wei P, Tolwani AJ, Fissell WH.
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):452-7. PubMed ID: 22282479
    [Abstract] [Full Text] [Related]

  • 28. An improved high-performance liquid chromatographic method with a solid-phase extraction for the determination of piperacillin and tazobactam: application to pharmacokinetic study of different dosage in Chinese healthy volunteers.
    Xia CH, Xiong YQ, Wang GJ.
    Biomed Chromatogr; 2007 Jul; 21(7):680-6. PubMed ID: 17385803
    [Abstract] [Full Text] [Related]

  • 29. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.
    Chung EK, Cheatham SC, Fleming MR, Healy DP, Shea KM, Kays MB.
    J Clin Pharmacol; 2015 Aug; 55(8):899-908. PubMed ID: 25823963
    [Abstract] [Full Text] [Related]

  • 30. Pharmacokinetics of YTR830H and piperacillin after intravenous coadministration.
    Cheung WK, Greene DS, Kuye O, Shin K, Tonelli AP, Houston A, Hibberd M, Faulkner RD, Silber BM.
    J Chemother; 1989 Jul; 1(4 Suppl):507-8. PubMed ID: 16312506
    [No Abstract] [Full Text] [Related]

  • 31. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulation and steady-state pharmacokinetic data from hospitalized patients.
    Rotschafer JC, Ullman M.
    Ann Pharmacother; 2009 Nov; 43(11):1887-9. PubMed ID: 19809005
    [Abstract] [Full Text] [Related]

  • 32. Therapeutic drug monitoring of piperacillin-tazobactam using spent dialysate effluent in patients receiving continuous venovenous hemodialysis.
    Connor MJ, Salem C, Bauer SR, Hofmann CL, Groszek J, Butler R, Rehm SJ, Fissell WH.
    Antimicrob Agents Chemother; 2011 Feb; 55(2):557-60. PubMed ID: 21115798
    [Abstract] [Full Text] [Related]

  • 33. Biliary elimination and hepatic disposition of an association of piperacillin and tazobactam: experimental evaluation.
    Brogard JM, Caro-Sampara F, Westphal JF, Blickle JF, Jehl F.
    Drugs Exp Clin Res; 1994 Feb; 20(6):247-55. PubMed ID: 7758397
    [Abstract] [Full Text] [Related]

  • 34. Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis.
    Mueller SC, Majcher-Peszynska J, Hickstein H, Francke A, Pertschy A, Schulz M, Mundkowski R, Drewelow B.
    Antimicrob Agents Chemother; 2002 May; 46(5):1557-60. PubMed ID: 11959598
    [Abstract] [Full Text] [Related]

  • 35. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements.
    Ulldemolins M, Martín-Loeches I, Llauradó-Serra M, Fernández J, Vaquer S, Rodríguez A, Pontes C, Calvo G, Torres A, Soy D.
    J Antimicrob Chemother; 2016 Jun; 71(6):1651-9. PubMed ID: 26869692
    [Abstract] [Full Text] [Related]

  • 36. Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under- and Overdosing.
    Jung B, Mahul M, Breilh D, Legeron R, Signe J, Jean-Pierre H, Uhlemann AC, Molinari N, Jaber S.
    Crit Care Med; 2017 May; 45(5):e470-e478. PubMed ID: 28240688
    [Abstract] [Full Text] [Related]

  • 37. Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.
    Thabit AK, Grupper M, Nicolau DP, Kuti JL.
    J Pharm Pract; 2017 Dec; 30(6):593-599. PubMed ID: 29121839
    [Abstract] [Full Text] [Related]

  • 38. Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam.
    Kim MK, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP.
    J Antimicrob Chemother; 2001 Aug; 48(2):259-67. PubMed ID: 11481298
    [Abstract] [Full Text] [Related]

  • 39. Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.
    Chen Y, Lu J, Dong M, Wu D, Zhu Y, Li Q, Chen C, Li Z.
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1479-1488. PubMed ID: 27644691
    [Abstract] [Full Text] [Related]

  • 40. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients.
    Cheatham SC, Fleming MR, Healy DP, Chung CE, Shea KM, Humphrey ML, Kays MB.
    Int J Antimicrob Agents; 2013 Jan; 41(1):52-6. PubMed ID: 23228881
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.